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Technical Report
Abstract
Purpose: The purpose of this technical study was to evaluate how the effect of changing beam energies for one to multiple frac-
tions of a patient’s plan affected the overall dose delivered to the planning target volume (PTV) and surrounding organs at risk
(OAR’s). Method: In this study, twenty-eight patient plans from treatment sites including the oesophagus, prostate, lung, spine,
rectum, bladder, chest, scapula, and breast were evaluated in the Philips Pinnacle treatment planning system (TPS), of these 14
were originally planned with 15MV and 14 with 10MV. Each of these plans were substituted with a single to multiple fractions
with 10MV and 15MV respectively while keeping the original monitor units the same. Results: It was determined that when
the number of fractions of the substituted beam energy remained at one fifth or less of the overall fractions a change of dose of
less than 2% to the PTV could be maintained. The OAR’s dose, when the plan had 20% of its fractions substituted with a dif-
ferent energy, were found to change by on average up to 3.5% and 2.3% for original plan energies of 15MV and 10MV respec-
tively. The dose change calculated in the TPS was then verified using ion chamber measurements for bladder and oesophagus
treatment plans. Conclusion: Results appear to indicate that the site of treatment was not an important factor when changing
energy but the overall number of fractions versus the number of fractions substituted with an alternative energy was funda-
mental. These results may be clinically useful when a radiotherapy department have machines with different photon energies.
In the event of a break down, when a patient needs to be urgently treated, it may be possible to treat them on another machine
with a different energy, without an immediate recalculation in the TPS. This decision would depend upon the percentage of
fractions of their overall treatment needing to be treated before the machine was repaired.
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Introduction
Murray Valley Radiation Oncology Centre has two linear
accelerators with different photon energies; a Varian 21iX
with 6MV and 10MV photon beams and a Varian 21eX with
6MV and 15MV photon energies.1 Problems arise when pa-
tients planned with 10MV or 15MV cannot be treated due to
the machine with that energy capability breaking down. As
this department is in a rural setting the patients cannot be
treated in another department due to the distance of travel
involved.
Previous studies have compared the same treatment plan
being carried out on two separate energies for the entire
duration of the treatment. In one study the difference be-
tween 6MV and 18MV for treatment of lung cancer was
evaluated and it was observed that there was no clinically
significant difference.2 However these plans had been recal-
culated and optimised in the treatment planning system. It
was found in another study that low energy beams provided
better conformity to the target than high energy beams due
to reduced lateral scatter.3
In a more recent study by Molazeda et al.4 oesophageal and
pelvis plans were compared using both 6MV and 15MV
where all parameters entered in the treatment planning sys-
tem (TPS) such as beam angle and weighting were kept the
same. It was established that there was no significant differ-
ence in uniform dose coverage to the PTV in both the oeso-
phageal and rectum plans when the energy was changed in
the TPS. However it should be noted that in the study by
Molazeda et al. the plan was recomputed to find the optimal
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monitor unit (MU) from each angle. This differs from what is
being conducted in this technical note where all parameters,
including the MU’s are kept the same, and the plan recom-
puted to find the difference to the PTV and OAR’s.
The purpose of this technical study was to investigate
whether a patient could have treatment between one and
several fractions of their whole treatment with substituted
beam energy and to quantify the difference in dose to the
planning target volume (PTV) and organs at risk (OAR).
Methods and Materials
Computation using TPS
The TPS used in this study was Pinnacle (Philips Healthcare,
Andover, MA) version 9.2.5 A variety of treatment plans
generated using three dimensional conformal radiation
therapy (3DCRT) were selected from the TPS with treatment
sites including the oesophagus, prostate, lung, spine, rectum,
bladder, chest, scapula and breast. Of the 28 plans selected
half were planned with 15MV and half with 10MV. The
number of fractions ranged from palliative treatments with 5
fractions to radical treatments with 34 fractions. In each case
the energy of a single fraction was changed to 15MV if the
plan was originally 10MV and 10MV if the original plan was
15MV. This was then repeated with 2, 3, 4, 5, 10 and all frac-
tions being changed either to 15MV or 10MV. The modified
treatment plan retained the same number of monitor units as
the original plan. The calculation algorithm used in the TPS
was collapsed cone convolution with a 0.28cm grid size. The
percentage changes to the mean dose of the PTV and OAR’s
were evaluated. The average PTV volume for the plans in-
vestigated is shown in Table 1.
TABLE 1: Average PTV volume for plans investigated.











Two bladder treatment plans were transferred onto a cylin-
drical phantom. The isocenter of the plans was moved to
allow the ion chamber to be located within the PTV. The
plan was modified so that trial 1 contained 5 fractions with
15MV and trial 2 with 4 fractions of 15MV and 1 fraction of
10MV. This second trial allowed for 20% of the treatment
plan to be delivered with 10MV. The dose to the isocentres
was recorded from the TPS for both trials. Both trials of the
oesophagus plans were delivered to the cylindrical phantom
with a Wellhofer cc13 chamber (Wellhofer Dosimetrie,
Schwrazenbruck Germany) 6 (with a collecting volume of
0.13cm3 and previously known as an IC15) inserted at the
centre. The ion chamber measurements were then compared
with the TPS results.
Similarly two oesophagus treatment plans were transferred
to a cylindrical phantom dataset where two plan trials were
created. Trial 1 contained 5 fractions of 10MV and trial 2
contained 4 fractions of 10MV and 1 fraction of 15MV. Ion
chamber measurements from the oesophagus trials were
compared to the results from the TPS.
FIG. 1: A plot showing the change in the PTV dose when a percent-
age of the treatment was substituted with 15MV instead of the orig-
inal planned 10MV for (a) three oesophagus plans, a spine plan, two
bladder plans, a chest plan and two lung plans and (b) five prostate
plans.
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Results
Computation using TPS
Each of the patient plans investigated were plotted using the
percentage change in dose to the PTV as a function of the
percentage of fractions with the substituted energy. These
findings are shown in Figure 1 for a 10MV plan with 15MV
substituted in for various numbers of fractions and Figure 2
where a 15MV treatment plan had various numbers of frac-
tions substituted with 10MV. Each of the different symbols
represents an individual patient plan. The percentage change
in the PTV dose was calculated using equation 1 where plan
A is the dose to the PTV in the original plan and plan B is
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FIG. 2: A plot showing the change in the PTV dose when a percent-
age of the treatment was substituted with 10MV instead of the orig-
inal planned 15MV for (a) a rectum plan, a spine plan, a chest plan
and breast plan and (b) eight prostate plans.
The percentage change in the dose to the OARs were tabu-
lated for each treatment plan when a fifth of the fractions
had been substituted with 15MV for a 10MV plan, Table 1,
and 10MV for a 15MV plan, Table 2.
TABLE 2: Percentage change for a fifth of the fractions of a 10MV
plan substituted with 15MV for the organs at risk (OARs)
Treatment Site OAR Average of changes to
Mean dose %
R Lung Spinal Cord 0.3
Heart 1.4
Bladder Left femur 3.9
Right Femur 1.9















TABLE 3: Percentage change for a fifth of the fractions of a 15MV
plan substituted with 10MV for the organs at risk (OARs).
























The TPS results for the bladder and oesophagus treatment
plans are compared with ion chamber measurements, shown
in Table 4. Trial 1 for the bladder treatment plans refers to 5
fractions of 15MV and trial 2 refers to 4 fractions of 15MV
and 1 fraction of 10MV. Similarly for the Oesophagus trial 1
refers to 5 fractions of 10MV and trial 2 refers to 4 fractions
of 10MV and 1 fraction of 15MV.
4 Hawke et al.: Evaluation of planned dosimetry International Journal of Cancer Therapy and Oncology
www.ijcto.org
Copyright © Hawke et al. ISSN 2330-4049
TABLE 4: TPS calculation compared to ion chamber measurements
for bladder and oesophagus treatment sites
Treatment Site ∆a ∆b
Bladder 1.2 0.6
Oesophagus 1.1 0.9
Abbreviations: ∆a = Average % difference between ion chamber
measurement of Trial 1 and 2; ∆b = Average % difference between
TPS and ion chamber measurement
Discussion and Conclusion
It can be seen from Figure 1 that when the 15MV beam is
substituted in for a 10MV plan the change to the PTV ap-
pears to follow a linear relationship with the number of frac-
tions substituted. A similar phenomenon was also seen in
Figure 2. More importantly the majority of the plans when
substituted with 15MV for 20% of the fractions have a cor-
responding change in dose to the PTV of <2%. This is con-
sistent with a study by Pokharel S7 where 6MV prostate
plans where substituted with mixed energy plans of 6MV
and 16MV and the total dose to the PTV was found to vary
by less than 1% from the original plan.
The International Commission on Radiation Units and
Measurements (ICRU) recommend that the PTV dose re-
mains within +7% and -5% of the prescription dose; there-
fore when considering if a plan could have one or multiple
fractions with a substituted energy the dose to the PTV and
the prescription dose needs to be considered.8
From Table 2, it is apparent that the average change to the
OAR’s for a substitution of a 15MV beam for 20% of a 10MV
plan varies between 0.3% to 3.9%. For a 15MV plan substi-
tuted with 10MV for 20% of the fractions shows that on
average the OAR’s have a change of <2.3%. These findings
are detailed in Table 3.
It was determined that up to 20% of the fractions for a 10MV
or 15MV plan could be substituted with 15MV or 10MV
respectively while maintaining the change to the PTV dose
of less than 2%. These findings could be used as a general
rule of thumb only for treatment plans generated using the
3DCRT technique in conjunction with the collapsed cone
convolution algorithm and not for other techniques such as
IMRT or VMAT.
These results were then verified using ion chamber meas-
urements and comparing to the TPS results. It was seen from
Table 4 that the difference between ion chamber measure-
ments and the treatment planning calculations were 1% or
less, this can be attributed to the relative output for 10MV
and 15MV being 1% above the ideal.
Neutron dose from the 15MV beam was not considered in
this study as it has previously been shown that the absolute
lifetime risk of malignancies caused by secondary neutrons
in a 15MV beam during intensity modulated radiation ther-
apy (IMRT) only increased slightly compared to the risk for a
6MV IMRT treatment.9 3DCRT has only a portion of the
MU’s delivered during IMRT and thus considered to have
even less risk than IMRT treatment plans. The results here
indicate the factors which need to be considered when sub-
stituting energy in for the planned energy are the number of
fractions which will have a substituted energy as a percent-
age of the overall treatment.
Whilst beam substitution is not the recommended approach
to treat patients when they are unable to be treated with the
planned energy, this technical study suggests that patient
dosimetry is not greatly affected if a treatment plan of 15MV
or 10MV were to be substituted with 10MV or 15MV re-
spectively for up to a fifth of the number of fractions.
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